This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acquired coagulation factor deficiency후천성 응고인자결핍 (후천응고인자결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.4 (Acquired coagulation factor deficiency) | Special Copayment Reduction: V284 (severe intractable disease, 5 years)
B. SynonymsAcquired coagulation factor deficiency, acquired coagulation factor inhibitor (autoantibody mechanism), acquired hemophilia (especially with anti-FVIII autoantibody), factor-specific names such as acquired factor VIII deficiency and acquired factor X deficiency; Acquired coagulation factor deficiency, Acquired factor deficiency, Acquired coagulopathy, Acquired hemophilia A/B
C. Adult onsetPossibility of first presenting in adulthood Very high — by definition an acquired disease, with almost all occurrences after adulthood (especially in the elderly). The median age at diagnosis of acquired hemophilia A is 75 years, and coagulation factor deficiency accompanying vitamin K deficiency, liver disease, and amyloidosis is also in principle of adult onset. Exceptionally, autoimmune disease- or pregnancy-related occurrence is possible in young women.
1. History1930s discovery of vitamin K (Dam, Doisy) → 1940s-60s liver disease-coagulopathy association elucidated → 1961 first description of acquired FVIII inhibitor → 1970s amyloidosis-factor X deficiency reported → 1980s-90s international registry studies such as EACH2 → 2017 introduction of non-factor therapeutics such as emicizumab opens a new chapter.
2. CausesVitamin K deficiency (malnutrition, malabsorption, antibiotics, obstructive jaundice), liver disease (cirrhosis, acute liver failure), disseminated intravascular coagulation (DIC), amyloidosis (adsorption of FX and FII), autoantibody inhibitors (acquired hemophilia A-D, acquired FV, FII, and FX inhibitors), nephrotic syndrome (urinary loss of FIX), drugs (warfarin, antibiotics, some antibiotics).
3. GeneticsNot a hereditary disease; somatic immunological background. In acquired hemophilia A, associations with HLA-DRB1*16 and HLA-DQA1*0102 have been reported; IL-10 and CTLA-4 polymorphisms are related to the tendency to form autoantibodies. A certain autoimmune predisposition (HLA class II background) contributes to susceptibility to inhibitor development.
4. General epidemiologyAcquired hemophilia A: about 1-1.78 per million per year, 3-4 per million in those 60 and older. Median age at diagnosis 75 years; bimodal distribution (young postpartum women + the elderly). FX deficiency accompanies about 8-14% of patients with AL amyloidosis. Coagulopathy related to vitamin K deficiency and liver disease is very common, but registration under code D68.4 is rare.
5. Pathophysiology① Autoantibody inhibitors: IgG4 antibodies against FVIII and others neutralize factor function or promote its clearance. ② Vitamin K deficiency: impaired gamma-carboxylation of the Gla domains of FII, FVII, FIX, and FX → production of inactive PIVKA. ③ Liver disease: decreased factor synthesis + hyperfibrinolysis + thrombocytopenia. ④ Amyloidosis: FX (and FII, FV, FVII) is adsorbed and removed by amyloid fibrils. ⑤ DIC: factor consumption due to coagulation hyperactivation.
6. SymptomsSpontaneous muscle hematoma and soft tissue hematoma (pectoralis major, iliopsoas, forearm, etc.), extensive subcutaneous ecchymosis, gastrointestinal bleeding, urinary hematuria, retroperitoneal hematoma, hemarthrosis (rare), and excessive bleeding after invasive procedures or surgery. In the inhibitor mechanism, newly occurring unexplained spontaneous bleeding is characteristic.
7. SignsPeriorbital ecchymosis (raccoon eyes, amyloidosis), extensive soft tissue hematoma, prolongation of PT and APTT alone or together, normal platelet count (in simple inhibitors), non-correction on mixing study (inhibitor), decreased FVIII activity, positive Bethesda titer, thrombocytopenia and prolonged PT in liver disease.
8. ScreeningNo general population screening. Regular PT and APTT monitoring in high-risk groups (liver disease, known hematologic malignancy or autoimmune disease, pregnant women, the elderly, patients on anticoagulants such as warfarin). In patients with unexplained bleeding, a coagulation screening panel (PT, APTT, TT, fibrinogen, platelets) is performed as first-line screening.
9. DiagnosisCoagulation screening (PT, APTT, TT, fibrinogen) → mixing study (differentiating deficiency from inhibitor by correction) → measurement of individual factor activity (FVIII, FIX, FX, etc.) → Bethesda assay (quantifying the inhibitor) → testing for underlying disease (liver function, vitamin K status, protein electrophoresis, bone marrow biopsy). Differentiating the cause is decisive for establishing the treatment plan.
10. Treatment① Treatment of the cause (vitamin K administration, liver disease management, anti-plasma-cell therapy for amyloidosis). ② Acute bleeding: FFP, PCC, factor concentrates, rFVIIa, aPCC (FEIBA). ③ Inhibitor eradication: steroids ± cyclophosphamide ± rituximab (immunosuppressive therapy); ITI. ④ Emicizumab (acquired hemophilia A, bleeding prevention when an inhibitor is present).
11. PrognosisVitamin K deficiency has an excellent prognosis after treatment. Acquired hemophilia A: overall mortality 9-41%; complete remission rate with immunosuppressive therapy about 60-80%. Main causes of death: bleeding (about 30%) and infection complicating immunosuppression (about 30%). FX deficiency accompanying amyloidosis: depends on the result of treatment of the underlying amyloidosis.
12. PreventionPrevention of vitamin K deficiency (adequate nutrition, supplementation during long-term antibiotic administration), regular INR monitoring in warfarin users, management of the cause of liver disease (abstaining from alcohol, treating viral hepatitis), correction of coagulation factors before surgery, early detection of bleeding signs in patients with known autoimmune disease.
13. ReferencesFranchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008 … and 9 other papers

1. History

The history of acquired coagulation factor deficiency unfolded together with the process of identifying the causes of hemorrhagic predisposition. Systematic understanding of the coagulation process itself began in the late 19th to early 20th century, when concepts of fibrin formation, the role of platelets, and coagulation proteins were gradually established. However, recognition that coagulation factors can become deficient after birth came stepwise through several major discoveries.

One of the oldest causes of acquired coagulation factor deficiency is vitamin K deficiency. In 1929 the Dane Henrik Dam, while studying cholesterol metabolism, observed an idiopathic hemorrhagic syndrome in chickens, and in 1935 he confirmed the absence of the fat-soluble substance that causes it and named it 'Koagulations-vitamin' (coagulation vitamin), that is, vitamin K. In the same year the American Edward Doisy elucidated the chemical structure of vitamin K, and the two jointly received the Nobel Prize in Physiology or Medicine in 1943. This discovery laid the foundation for understanding the existence of vitamin K-dependent coagulation factors (prothrombin, factors VII, IX, and X) and that coagulopathy occurs in nutritional deficiency or malabsorption.

The history of acquired coagulation factor deficiency related to warfarin is also important. In the 1940s the Canadian Karl Paul Link observed that dicoumarol extracted from spoiled clover caused excessive bleeding in cattle, which led to the development of warfarin as a rat poison in 1948 and as an anticoagulant in 1954. As it was elucidated that the mechanism of action of warfarin is inhibition of the synthesis of vitamin K-dependent coagulation factors, the most common model of drug-induced acquired coagulation factor deficiency was established.

The association between liver disease and coagulopathy has long been observed clinically, but understanding of the molecular mechanism came after the mid-20th century. As hepatocytes were confirmed in the 1950s-60s to be the main site of synthesis of coagulation factors (prothrombin, factors V, VII, IX, and X, fibrinogen, etc.), coagulopathy in cirrhosis and acute liver failure began to be explained as multifactorial decreased synthesis beyond simple vitamin K deficiency.

Acquired coagulation factor deficiency due to autoantibody inhibitors came to be recognized as an independent clinical entity in 1961, when Feinstein and Rapaport first clearly described anti-FVIII autoantibodies (acquired hemophilia A) in non-hemophilic patients. Acquired hemophilia A was subsequently established as a rare bleeding emergency associated with various underlying conditions such as autoimmune disease, malignancy, the postpartum period, and drugs. In the 1980s-90s, autoantibodies against factor V, factor II, factor X, and vWF were also reported, expanding the spectrum of acquired coagulation factor deficiency.

The association between amyloidosis and factor X deficiency was first described in 1962 by Pechet and Alexander. They reported that in patients with primary (AL-type) amyloidosis, factor X is adsorbed and removed by amyloid fibrils, causing severe bleeding, and deficiencies of factors II, V, VII, and IX were later also reported in amyloidosis. From the 1990s, the biochemical mechanism of coagulation factor adsorption by amyloid fibrils was elucidated.

In treatment history, acquired hemophilia A depended mainly on fresh frozen plasma (FFP) and steroids until the late 20th century. With the introduction of activated prothrombin complex concentrate (aPCC, FEIBA) and recombinant activated factor VII (rFVIIa, NovoSeven) as bypassing therapy in the 1980s-90s, control of acute bleeding became possible. In the 2000s, immunosuppressive therapy including rituximab was shown to be effective for eradicating inhibitors, and in 2012 the European Acquired Haemophilia Registry (EACH2) provided large-scale epidemiological and clinical data. After emicizumab received FDA approval in 2017 for congenital hemophilia A with inhibitors, it began to be applied for bleeding prevention in acquired hemophilia A as well, and its usefulness was validated through studies such as GTH-AHA-EMI in 2024-25.


2. Causes

Acquired coagulation factor deficiency (ICD-10 D68.4) is, unlike hereditary deficiency, a heterogeneous group of diseases in which synthesis of a specific coagulation factor is reduced or its function lost after birth due to various endogenous and exogenous causes. The causes are broadly classified as ① decreased coagulation factor synthesis, ② adsorption, consumption, or loss of coagulation factors, ③ autoantibody inhibitors, and ④ drug-induced.

Vitamin K deficiency

Vitamin K is a fat-soluble vitamin essential for gamma-carboxylation of factors II (prothrombin), VII, IX, and X, protein C, protein S, and protein Z in the liver. The main causes of vitamin K deficiency are malnutrition (prolonged fasting, extreme dietary restriction), malabsorption (celiac disease, short bowel syndrome, inflammatory bowel disease, fat malabsorption due to biliary secretory insufficiency), obstructive jaundice (bile acids are needed for intestinal vitamin K absorption), broad-spectrum antibiotic administration (blocking vitamin K₂ synthesis by intestinal bacteria), hemorrhagic disease of the newborn (insufficient placental transfer + low content in breast milk), and antituberculosis drugs (rifampin accelerates vitamin K metabolism). In vitamin K deficiency, factor VII (shortest half-life, 4-6 hours) falls first so that PT is prolonged first, followed by decreases in factors IX, X, and II in that order.

Liver disease

Hepatocytes are the main site of synthesis of factors I (fibrinogen), II, V, VII, IX, X, XI, and XII and of coagulation regulatory factors (protein C, S, and Z, antithrombin). In cirrhosis, acute liver failure, alcoholic hepatitis, and viral hepatitis, decreased hepatocyte function reduces the synthesis of many coagulation factors simultaneously. In addition, platelet sequestration due to splenomegaly (hypersplenism) and thrombocytopenia, hyperfibrinolysis (increased tissue plasminogen activator), dysfibrinogenemia, and reduced vitamin K absorption act in combination. In acute liver failure, PT and INR rise sharply due to abrupt loss of coagulation factors from hepatocyte necrosis, and they are also used as prognostic indicators.

Disseminated intravascular coagulation (DIC)

Sepsis, trauma and multiple organ injury, obstetric complications (placental abruption, amniotic fluid embolism, eclampsia), malignancy, extensive burns, transfusion reactions, and so on cause hyperactivation of the coagulation system within blood vessels, so that coagulation factors and platelets are consumed and depleted. In DIC, many factors are deficient at the same time, producing a clinical picture in which bleeding and thrombosis coexist.

Amyloidosis

In primary AL (light chain) amyloidosis, amyloid fibrils nonspecifically adsorb and remove factor X, sharply lowering blood FX levels. This is explained by the binding of a specific surface structure of amyloid fibrils to the Gla domain of FX. FX deficiency accompanies about 8-14% of patients with AL amyloidosis, and deficiencies of factors II, V, VII, and IX also rarely accompany it. FX deficiency is an independent bleeding risk factor in AL amyloidosis.

Autoantibody inhibitor

A case in which autologous IgG antibodies against a specific coagulation factor form in a non-hemophilic patient and neutralize or accelerate clearance of that factor is called an inhibitor. The most common is acquired hemophilia A (anti-FVIII autoantibody), whose underlying conditions include autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.), malignancy (hematologic and solid cancers), pregnancy and the postpartum period, drugs (penicillin, interferon, etc.), and idiopathic (about 50%). Acquired factor V inhibitors often occur after exposure to bovine thrombin, and can also occur as alloantibodies after transfusion or surgery. Acquired factor II inhibitors may appear in association with antiphospholipid syndrome (APS).

Nephrotic syndrome and others

In nephrotic syndrome, factor IX (molecular weight 57 kDa) is lost in the urine through proteinuria, which can cause acquired FIX deficiency. Factor XII deficiency is not related to clinical bleeding but prolongs APTT, so differentiation is important. Other causes include dilutional coagulopathy after massive transfusion and reduced coagulation enzyme function due to hypothermia.


3. Genetics

Acquired coagulation factor deficiency (D68.4) is by definition not a congenital deficiency due to a gene variant and has no direct causal relationship with a specific germline mutation. However, when autoantibody inhibitors form—especially in acquired hemophilia A—a genetic predisposition related to breakdown of immune tolerance is known to be partially involved.

HLA association: the association of HLA class II genotypes has been studied in patients with acquired hemophilia A. Some studies report that HLA-DRB1*16:01, HLA-DQA1*0102, and HLA-DQB1*0502 are statistically associated with the occurrence of acquired hemophilia A. This suggests that specific MHC class II molecules may effectively present specific peptide epitopes of FVIII to autoreactive CD4+ T cells, promoting autoantibody formation. However, results of HLA association studies are inconsistent between studies, so it is difficult to predict onset from a single HLA genotype alone.

Immunoregulatory genes: gene polymorphisms that determine the tendency toward autoimmunity may influence inhibitor formation in acquired coagulation factor deficiency. CTLA-4 (cytotoxic T-lymphocyte antigen 4) gene polymorphisms (+49A/G, etc.) are associated with autoimmune disease in general and have also been explored in acquired hemophilia A. IL-10 promoter polymorphisms affect IL-10 production levels, which are involved in regulatory T-cell function and maintenance of immune tolerance to FVIII. TNF-α genotypes have also been explored in acquired hemophilia associated with underlying autoimmune disease, but results are not yet consistent.

Genetic predisposition to underlying autoimmune disease: a considerable proportion (about 10-15%) of acquired hemophilia A accompanies other autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Graves disease, and Sjögren syndrome. In these cases, genetic risk factors of the autoimmune disease itself (HLA class II background, gene polymorphisms such as PTPN22, STAT4, and IRF5) may constitute the genetic background for the development of acquired hemophilia.

Amyloidosis and acquired FX deficiency: AL amyloidosis arises from monoclonal proliferation of plasma cells, and somatic mutations of immunoglobulin light chain genes determine the tendency to form amyloid fibrils. However, the genetic risk factor for AL amyloidosis itself is mainly acquired genomic instability related to progression of monoclonal gammopathy of undetermined significance (MGUS), not germline gene variants. Coagulation factor deficiency can also rarely accompany hereditary transthyretin amyloidosis (hATTR), which is a hereditary disease caused by TTR gene variants (Val30Met, etc.).

Genetics related to vitamin K deficiency: acquired vitamin K deficiency itself is unrelated to heredity, but polymorphisms of VKORC1 (vitamin K epoxide reductase complex subunit 1) and CYP2C9 influence warfarin sensitivity, so the degree of coagulation inhibition at the same dose differs between individuals. In particular, the VKORC1 -1639G>A polymorphism and CYP2C9*2 and *3 variants markedly reduce the required warfarin dose and raise the risk of excessive anticoagulation. This is used for individualizing warfarin dosing from the pharmacogenomics perspective.


4. General epidemiology

Acquired coagulation factor deficiency is a heterogeneous group of diseases whose prevalence and epidemiological characteristics differ greatly by cause. Acquired coagulation factor deficiency in the broad sense (liver disease, vitamin K deficiency, DIC, etc.) is very common in hospitalized patients, whereas acquired deficiency due to autoantibody inhibitors in the narrow sense (especially acquired hemophilia A) is a rare disease.

Acquired hemophilia A (anti-FVIII autoantibody)

This is the best-studied form of acquired coagulation factor deficiency, with a worldwide annual incidence reported as about 1-1.78 per million per year. It increases to about 3-4 per million per year in the elderly aged 60 and older and is higher still in the very elderly aged 80 and older. The median age at diagnosis is about 75 years, and about 80% of all patients occur in the elderly aged 65 and older. In sex distribution, males are slightly predominant overall (about 1.2:1), but it shows a bimodal distribution. The first peak is in women in their 20s-40s, occurring in pregnancy and the postpartum period (about 7-9%), and the second peak occurs in the elderly in their 70s-80s without sex difference. In the European EACH2 registry study (2003-2008, 501 patients), autoimmune disease (18%), malignancy (12%), skin disease (8%), and pregnancy/postpartum (7%) were reported as underlying conditions, and about 50% were idiopathic.

Amyloidosis and acquired FX deficiency

FX deficiency occurs in about 8-14% of patients with AL amyloidosis, and it is the most common acquired coagulation factor deficiency in amyloidosis. In a worldwide epidemiology review published in Tandfonline in 2025, acquired FX deficiency was identified as an independent risk factor for bleeding and death in AL amyloidosis. Because the worldwide annual incidence of AL amyloidosis is about 8-12 per million per year, amyloidosis-associated acquired FX deficiency is estimated at about 0.6-1.7 per million per year.

Epidemiology by other causes

Vitamin K deficiency-related coagulopathy is common in neonates (about 1/1,000 live births), intensive care unit patients, patients on long-term antibiotics, and patients with malabsorption, but the frequency of registration and reporting under ICD-10 D68.4 is low. Acquired FV inhibitors are very rare, with fewer than about 200 case reports worldwide since 1970. Acquired FII inhibitors and other factor inhibitors are also rare, and most of the literature is at the case report level.

Epidemiology in Korea

Precise epidemiological data on acquired coagulation factor deficiency in Korea are limited. It can be indirectly grasped through the number of patients registered for Special Copayment Reduction (V284) in Health Insurance Review & Assessment Service claims data and rare disease registration data. According to reports from the Korean Society of Hemophilia and the Korea Hemophilia Foundation, the occurrence of acquired hemophilia A in Korea is on an increasing trend with population aging, but its incidence is estimated to be at a level similar to the West (1-2 per million per year). Cases of acquired FX deficiency accompanying AL amyloidosis have also been reported in the Korean literature (Lee et al., Korean J Hematol, 2011). With the entry into an aging society, the occurrence of acquired hemophilia A is predicted to continue to increase in the future.


5. Pathophysiology

The pathophysiology of acquired coagulation factor deficiency differs greatly depending on the cause, and understanding each mechanism is essential for accurate diagnosis and treatment.

Autoantibody inhibitor mechanism (focus on acquired hemophilia A)

In acquired hemophilia A, autologous IgG antibodies (mainly the IgG4 subclass) against FVIII are produced and interfere with coagulation function. They are classified into two types according to the functional characteristics of the inhibitor. Type I shows stoichiometric neutralization, binding to FVIII 1:1 and completely neutralizing its activity. In this case a linear decrease is seen on the Bethesda curve. Type II shows complex kinetics, does not completely neutralize FVIII so that some residual activity remains, and the Bethesda curve is nonlinear. Inhibitors in acquired hemophilia A mostly show type II kinetics, so residual FVIII activity remains low. Inhibitors recognize the A2 domain (FIXa and FX binding site) and C2 domain (phospholipid and vWF binding site) of FVIII as the main epitopes. In addition to directly neutralizing FVIII function, autoantibodies accelerate macrophage-mediated clearance of FVIII via FcγR, shortening the FVIII half-life.

Immunopathophysiologically, peripheral immune tolerance breaks down, autoreactive CD4+ T cells against FVIII are activated, and B cells differentiate into plasma cells and continuously produce autoantibodies. Decreased regulatory T-cell (Treg) function, increased presentation of self-epitopes by dendritic cells, and binding of FVIII peptides by specific HLA class II molecules are involved in this process. Underlying autoimmune disease, immune dysregulation due to malignancy, and a Th2-biased immune environment in pregnancy act as triggering factors for autoantibody formation.

Mechanism of vitamin K deficiency

Vitamin K acts as a cofactor of the enzyme (GGCX, γ-glutamyl carboxylase) that converts Glu (glutamic acid) residues of the precursor proteins of factors II, VII, IX, and X and proteins C, S, and Z to Gla (γ-carboxyglutamic acid) in the liver. The Gla domain binds to phospholipid surfaces (especially anionic phospholipids) via calcium ions (Ca²⁺) and is essential for forming coagulation complexes on phospholipid surfaces. In vitamin K deficiency, the Gla domain is not properly formed, and inactive precursors called PIVKA (Protein Induced by Vitamin K Absence or Antagonism) accumulate in the blood. These cannot perform coagulation function, and PIVKA-II (undercarboxylated prothrombin) is also used as a tumor marker of hepatocellular carcinoma.

Mechanism in liver disease

Coagulopathy in liver disease is understood through the concept of rebalancing, going beyond simple coagulation factor deficiency. That is, anticoagulant proteins (protein C and S, antithrombin) also decrease at the same time, so a bleeding-thrombosis imbalance occurs rather than a simple bleeding tendency. The main mechanisms include ① decreased synthesis of many coagulation factors such as vitamin K-dependent factors, factor V, and fibrinogen, ② hyperfibrinolysis due to decreased hepatic clearance of tissue plasminogen activator (tPA), ③ induction of DIC by release of tissue factor during hepatocyte necrosis, ④ platelet sequestration due to splenomegaly, and ⑤ dysfibrinogenemia (increased sialic acid content of fibrinogen → impaired fibrin polymerization).

Mechanism in amyloidosis

In AL amyloidosis, amyloid fibrils have a strong affinity for the positively charged surface Gla domain and nonspecifically adsorb factor X (which carries a Gla domain) circulating in the blood. This adsorption is irreversible, and the greater the total amyloid burden in the body, the more severe the decrease in FX. Factors II, VII, and IX also carry Gla domains and can be adsorbed by a similar mechanism, but FX is most commonly affected. Because FX deficiency by this mechanism is due to direct adsorption by amyloid fibrils, even when exogenous FX such as FFP or FX concentrate is administered, the administered FX is rapidly adsorbed and removed, and the therapeutic effect is limited.

DIC mechanism

In DIC, overexpression of tissue factor (TF) or coagulation hyperactivation in damaged cells and vascular endothelium produces excess thrombin, and fibrin thrombi widely occlude the microvasculature. Coagulation factors (mainly including fibrinogen and factors V and VIII) and platelets are consumed and depleted, and at the same time secondary fibrinolysis is enhanced so that already formed thrombi are dissolved, resulting in simultaneous bleeding and thrombosis. Elevated D-dimer and fibrin degradation products (FDP), decreased fibrinogen, and thrombocytopenia are characteristic findings.


6. Symptoms

The clinical symptoms of acquired coagulation factor deficiency vary depending on the type of deficient factor, the degree of deficiency, and the underlying cause. In particular, cases caused by autoantibody inhibitors (acquired hemophilia A) show a characteristic bleeding pattern distinct from congenital hemophilia.

Spontaneous bleeding and soft tissue bleeding

The most characteristic symptoms in acquired hemophilia A are spontaneous muscle hematoma and extensive soft tissue hematoma. Hematomas form in large muscles such as the pectoralis major, iliopsoas, forearm, buttocks, and thigh, and occur without trauma or with minor stimulation. This contrasts with the recurrent hemarthrosis of severe congenital hemophilia. Bleeding progresses slowly to form extensive hematomas and may compress nerves (femoral nerve, radial nerve, etc.) or blood vessels, causing nerve palsy or compartment syndrome.

Ecchymosis

Extensive subcutaneous ecchymosis appears as the first or most common symptom of acquired hemophilia A. Unlike congenital hemophilia, skin ecchymosis is markedly frequent, which is explained by the frequency of small vessel bleeding in the skin and mucosal supporting tissue in patients with autoantibody inhibitors. When accompanied by amyloidosis, periorbital/periocular ecchymosis (popularly called "raccoon eyes") is characteristic and reflects the fragility of vessels with amyloid deposition.

Gastrointestinal and urinary tract bleeding

Gastrointestinal bleeding (melena, hematochezia, hematemesis) and hematuria are common. Gastrointestinal bleeding can be the occasion for first discovering acquired hemophilia A in elderly patients, and a coagulation disorder should be suspected when endoscopy shows no specific causative lesion. Hematuria due to urethral mucosal bleeding may be persistent and recurrent.

Retroperitoneal hematoma

Retroperitoneal hematoma is a serious, life-threatening complication of acquired hemophilia A and can cause skin discoloration around the umbilicus or on the flanks of the abdomen (Cullen's sign, Grey Turner's sign). It should be suspected in elderly patients complaining of sudden abdominal or back pain.

Excessive bleeding after procedures and surgery

In patients with vitamin K deficiency, liver disease, or a mild inhibitor, the diagnosis is often first made through excessive bleeding at endoscopic biopsy, dental extraction, or surgery. When abnormalities are found on preoperative coagulation tests or hemostasis cannot be achieved after surgery, acquired coagulopathy should be actively differentiated.

Intracranial hemorrhage

Intracranial hemorrhage in acquired hemophilia A is uncommon, with an incidence of about 2-4%, but it is fatal when it occurs. A coagulation disorder must be excluded in elderly patients with headache of unknown cause, altered consciousness, or neurological deficits.

Symptoms related to vitamin K deficiency and liver disease

In vitamin K deficiency, symptoms of the underlying causative disease (malabsorption syndrome, obstructive jaundice, etc.) accompany the bleeding symptoms. In liver disease-related coagulopathy, the clinical symptoms of cirrhosis such as skin jaundice, ascites, hepatic encephalopathy, splenomegaly, and esophageal variceal bleeding are the main findings. In DIC, bleeding and thrombosis occur at the same time, with skin petechiae, purpura, necrosis, and organ ischemia occurring in combination.


7. Signs

The physical signs and laboratory findings of acquired coagulation factor deficiency vary by cause, and the bleeding site, extent, and signs of the underlying disease appear in combination.

Physical signs

The most common physical finding in acquired hemophilia A is extensive ecchymosis, widely distributed over the trunk and limbs. Hematomas expand and may show fluctuance on palpation, and the skin color changes from initial magenta to yellow-green over time. A large muscle hematoma compresses adjacent nerves and causes signs of nerve injury (sensory loss, muscle weakness, loss of reflexes). Periorbital ecchymosis ('raccoon eyes') is a characteristic sign when amyloidosis accompanies the disease and reflects fragility due to amyloid deposition in orbital fat and conjunctival vessels. Oral mucosal and gingival bleeding and epistaxis may accompany.

Test findings

The pattern seen on coagulation screening tests differs by cause. Isolated prolongation of APTT (activated partial thromboplastin time) suggests deficiency of intrinsic pathway factors (FVIII, FIX, FXI, FXII) or an inhibitor. In acquired hemophilia A, a pattern of markedly prolonged APTT (often >100 seconds) with normal PT is typical. Isolated prolongation of PT occurs in factor VII deficiency (early vitamin K deficiency or warfarin therapy). Simultaneous prolongation of PT and APTT suggests multiple factor deficiency (severe vitamin K deficiency, severe liver disease, DIC, common pathway factor deficiency). Platelet count is normal in simple inhibitors but decreased in DIC and cirrhosis. Fibrinogen is decreased in DIC and variable in liver disease.

The mixing study is the key test for differentiating the cause of APTT prolongation into factor deficiency or inhibitor. Patient plasma and normal plasma are mixed 1:1, and APTT is measured immediately and after 2 hours of incubation at 37°C. In factor deficiency, APTT is corrected by mixing, whereas with an inhibitor (especially an autoantibody), correction is poor or correction is lost after incubation. Inhibitors in acquired hemophilia A are time-dependent, so the inhibitory effect becomes more evident after incubation at 37°C. FVIII activity is markedly decreased (often <5 IU/dL), but vWF antigen and vWF activity are normal. Inhibitor quantification is measured in BU/mL by the Bethesda assay or the Nijmegen-modified Bethesda assay.

In vitamin K deficiency, elevated PIVKA-II (uncarboxylated precursor of protein C) is a sensitive early indicator and may appear before PT prolongation. In liver disease, abnormalities of bilirubin, AST, ALT, and albumin, thrombocytopenia, elevated INR, and decreased total protein accompany it, and liver function tests such as ICG testing are also abnormal. When amyloidosis accompanies the disease, a monoclonal protein (M-spike) is detected on serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), and an abnormal serum free light chain ratio (sFLC ratio), serum amyloid A (SAA), or AL amyloid-specific markers may appear.


8. Screening

Population-wide screening of the general population for acquired coagulation factor deficiency is not performed. However, coagulation screening tests and surveillance of underlying disease in specific high-risk groups play an important role in early diagnosis.

Patients on warfarin and anticoagulants

Regular PT/INR monitoring is standard for patients taking vitamin K antagonists (VKA, typically warfarin). When INR departs from the target range and supratherapeutic anticoagulation occurs, this is an acquired coagulation factor deficiency state corresponding to D68.4. The monitoring interval is based on 4 weeks in stable patients, and short-term retesting is needed immediately after a dose change or when an interacting drug is added.

Patients with liver disease

In patients with cirrhosis or acute liver failure, tests including a coagulation panel (PT, APTT, fibrinogen, platelets, INR) are performed at admission and at regular follow-up. PT/INR is used as a prognostic indicator in acute liver failure (King's College criteria). INR is included in the MELD score calculation in patients waiting for liver transplantation. Because coagulation changes in acute liver failure are highly dynamic, daily or frequent monitoring is needed.

Patients before surgery with bleeding risk

The usefulness of routine coagulation testing before elective surgery or invasive procedures is controversial, but a coagulation screening test including PT and APTT is recommended in patients with risk factors such as bleeding history, liver disease, malabsorption, or anticoagulant use. When abnormal PT or APTT is found before surgery, the cause must be identified first.

Patients with autoimmune disease and malignancy

When unexplained bleeding symptoms appear in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren syndrome and in patients with hematologic malignancy, the development of inhibitors including acquired hemophilia A must be actively excluded. In lupus, antiphospholipid antibodies (aCL, anti-β₂GPI, lupus anticoagulant) are followed regularly, and these also affect PT and APTT.

Pregnant and postpartum women

When unexplained spontaneous bleeding, especially soft tissue hematoma or excessive postpartum hemorrhage, appears in pregnant and postpartum women, acquired hemophilia A must be differentiated. PT and APTT screening tests during pregnancy are not routinely performed, but they are performed when there are signs of bleeding or when assessment of peripartum bleeding risk is needed.

Amyloidosis screening

In patients diagnosed with AL amyloidosis, baseline coagulation tests (including PT, APTT, and FX activity) are recommended at diagnosis and regular follow-up according to changes in amyloid burden. FX activity <50 IU/dL is regarded as clinically significant deficiency, and the bleeding risk increases markedly at FX activity <30 IU/dL.


9. Diagnosis

For the diagnosis of acquired coagulation factor deficiency, a stepwise approach including differentiation of the cause is essential. The three key goals of diagnosis are differentiation from congenital coagulation factor deficiency, confirmation of the presence of an inhibitor, and identification of the underlying causative disease.

Coagulation screening tests

Four tests, prothrombin time (PT)/international normalized ratio (INR), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen, form the basis of first-line screening. The pathway of the deficient factor is inferred from the combination of these results. Isolated APTT prolongation suggests deficiency of intrinsic pathway (FVIII, FIX, FXI, FXII) or common pathway (FX, FV, FII, Fg) factors, or an inhibitor. Isolated PT prolongation suggests the extrinsic pathway (FVII) or early vitamin K deficiency. Simultaneous prolongation of PT and APTT suggests common pathway factor deficiency, multiple factor deficiency, severe vitamin K deficiency, or DIC. TT prolongation suggests a fibrinogen abnormality or the presence of heparin.

Mixing study

When APTT (or PT) is prolonged, patient plasma and normal plasma are mixed 1:1 to check for correction. Both immediate measurement (immediate mix) and measurement after 1-2 hours of incubation at 37°C are performed. The Rosner index [100×(mixed APTT - normal APTT)/(patient APTT - normal APTT) <15%] is sometimes used as a criterion for correction. If corrected, factor deficiency is likely, and if correction is incomplete or prolongation increases after incubation, an inhibitor (autoantibody) is strongly suggested. APTT prolongation due to lupus anticoagulant (LA) shows immediate poor correction on mixing study, so differentiation is needed.

Measurement of individual coagulation factor activity

The activity of relevant factors is measured according to the mixing study results and the clinical situation. When acquired hemophilia A is suspected, FVIII activity (one-stage method, two-stage chromogenic substrate method) and vWF antigen and activity measurement are key. When vitamin K deficiency or liver disease is suspected, FII, FVII, FIX, and FX activity are measured together. When amyloidosis accompanies, FX activity (characteristic if isolated decrease) is measured first. Isolated decrease of FV activity suggests an FV inhibitor or liver disease, and isolated decrease of FII suggests lupus anticoagulant or anti-prothrombin antibody.

Inhibitor quantification test

When decreased factor activity is confirmed and an inhibitor is suspected, the inhibitor titer is measured in BU/mL by the Bethesda assay or the standardized Nijmegen-modified Bethesda assay. 0.6 BU/mL or higher is judged positive, and less than 5 BU/mL is classified as low titer and 5 BU/mL or higher as high titer. Inhibitors in acquired hemophilia A, unlike congenital ones, show type II (nonlinear) kinetics and may be underestimated under standard Bethesda conditions, so use of the Nijmegen modification is recommended.

Tests to identify the underlying cause

Tests to identify the cause of acquired coagulation factor deficiency are selected according to the clinical situation. To confirm vitamin K deficiency, serum vitamin K concentration or PIVKA-II can be measured. To evaluate liver disease, liver function tests (AST, ALT, ALP, bilirubin, albumin, PT), hepatitis B and C virus markers, and liver ultrasound or CT are performed. For amyloidosis screening, serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), serum free light chain (sFLC) ratio, and urine protein electrophoresis (UPEP) are performed, and for confirmation, Congo red-stained tissue biopsy (fat, bone marrow, rectal mucosa) is performed. To assess DIC, serial measurement of D-dimer, FDP, platelets, and fibrinogen is needed. To identify the underlying cause of acquired hemophilia A, autoantibody tests such as ANA, anti-dsDNA, and antiphospholipid antibodies, tumor markers, chest and abdominal CT, and consultation with dermatology and rheumatology are considered.

Imaging and other tests

Ultrasound or MRI is performed to determine the extent of the hematoma and whether nerves or vessels are compressed. Ultrasound is suitable for determining the extent of a muscle hematoma and the presence of septation, and MRI precisely evaluates the anatomical relationship with muscles, vessels, and nerves. When retroperitoneal hematoma is suspected, abdominal-pelvic CT is the standard.


10. Treatment

Treatment of acquired coagulation factor deficiency consists of three axes: ① control of acute bleeding (hemostatic therapy), ② treatment of the underlying cause, and ③ eradication of the inhibitor or supply of coagulation factors. The approach differs greatly by cause, and in the case of the inhibitor mechanism in particular, immunosuppressive therapy is key.

Treatment of vitamin K deficiency

Administration of vitamin K₁ (phylloquinone) is immediately effective. With intravenous administration (1-10 mg, slow injection), correction of PT begins within 6-12 hours and normalizes within 24-48 hours. Oral and subcutaneous administration are also possible, but intravenous administration is recommended in patients with malabsorption. In warfarin over-anticoagulation, vitamin K administration, temporary interruption of warfarin, or administration of four-factor prothrombin complex concentrate (4F-PCC) is decided according to the INR level and the presence of bleeding. For severe bleeding or emergency surgery, 4F-PCC (Beriplex, Kcentra, etc.) provides faster reversal than fresh frozen plasma (FFP) and is currently preferentially recommended in international guidelines.

Treatment of liver disease-related coagulopathy

The fundamental treatment of liver disease-related coagulopathy is management of the underlying liver disease (alcohol abstinence, antiviral treatment of viral hepatitis, liver transplantation, etc.). For acute bleeding or for correction of coagulation before invasive procedures, FFP, platelet transfusion, and fibrinogen concentrate (or cryoprecipitate) are used. However, large-volume FFP administration in patients with liver disease is greatly dose-limited and carries a risk of volume overload, so 4F-PCC or recombinant FVIIa is used selectively. Because PT/INR values alone tend to overestimate bleeding risk, an individualized transfusion strategy using viscoelastic testing such as platelet thrombus-forming capacity (TEG/ROTEM) is recommended. Tranexamic acid (TXA) can be used when hyperfibrinolysis accompanies (especially in acute liver failure and during liver transplant surgery).

Treatment of amyloidosis-related coagulation factor deficiency

The fundamental treatment of FX deficiency related to AL amyloidosis is reduction of amyloid burden through suppression of plasma cells. Anti-plasma-cell chemotherapy (bortezomib-based regimens: VCd, VMP, etc.) and autologous stem cell transplantation (ASCT) can restore FX activity. In acute bleeding, FFP or 4F-PCC (prothrombin complex concentrate) is used for temporary FX replacement, but because of FX adsorption by amyloid fibrils, the duration of effect may be short. FX concentrate (Coagadex) is used in some countries for treatment and prevention of FX deficiency related to AL amyloidosis, and a clinical trial (NCT06963216) is ongoing in 2025.

Treatment of acquired hemophilia A — control of acute bleeding

Because FVIII is neutralized by the inhibitor in acute bleeding of acquired hemophilia A, bypassing agents are the first choice. Recombinant activated factor VII (rFVIIa, NovoSeven) directly activates FXa on the platelet surface regardless of tissue factor to generate thrombin. The dose is 90-120 μg/kg repeated at 2-3 hour intervals and continued until bleeding is controlled. Activated prothrombin complex concentrate (aPCC, FEIBA) contains activated FVIIa, FIX, FX, and FII and bypasses the intrinsic pathway, and 50-100 IU/kg is administered at 8-12 hour intervals. Because rFVIIa and aPCC carry a risk of thrombosis, combined use is avoided in principle.

Emicizumab (Hemlibra) is a bispecific antibody that binds FIXa and FX simultaneously and substitutes for the function of FVIII. It is administered by subcutaneous injection (once weekly or once every two weeks) and is effective in preventing bleeding regardless of the presence of an inhibitor. In the GTH-AHA-EMI study in 2024-25, a strategy of starting emicizumab first and delaying or minimizing immunosuppressive therapy was reported to show a survival benefit. Combined use of aPCC during emicizumab administration carries a high risk of thrombotic complications and should be avoided or used with caution.

Treatment of acquired hemophilia A — eradication of the inhibitor (immunosuppressive therapy)

The treatment goal is to eliminate the inhibitor and achieve complete remission (inhibitor disappearance + FVIII normalization + discontinuation of immunosuppression). First-line immunosuppressive therapy is steroids alone or steroids + cyclophosphamide. The standard approach is prednisolone 1 mg/kg/day (maximum 80 mg/day) for 4-6 weeks followed by tapering, and adding cyclophosphamide 100-200 mg/day (or 2 mg/kg/day) raises the complete remission rate. In the EACH2 registry study, the complete remission rate was reported as about 70% with steroids + cyclophosphamide and about 48% with steroids alone. Rituximab (anti-CD20 monoclonal antibody) 375 mg/m² once weekly × 4 doses provides a complete remission rate (about 59%) similar to steroids + cyclophosphamide and is an alternative in the elderly or in patients at risk with steroids. Because immunosuppressive therapy carries a risk of serious infection, careful application is needed in the elderly and in patients with severe underlying disease.


11. Prognosis

The prognosis of acquired coagulation factor deficiency differs greatly depending on the cause, the underlying disease, the timing of treatment initiation, and the patient's overall condition.

Vitamin K deficiency

When the cause is removed and vitamin K is adequately supplemented, coagulation factors normalize within several days and the prognosis is excellent. Cases caused by warfarin over-anticoagulation also mostly recover after reversal treatment. However, the prognosis is poor if intracranial hemorrhage or other life-threatening bleeding occurred before reversal.

Liver disease-related coagulopathy

The prognosis of liver disease-related coagulopathy depends on the course of the underlying liver disease. If liver transplantation is successful, coagulation function recovers. In acute liver failure, PT/INR is used as a prognostic indicator, and spontaneous recovery is sometimes possible even without liver transplantation. In end-stage cirrhosis, the prognosis is very poor when combined coagulopathy is accompanied by variceal bleeding and peritonitis.

Acquired hemophilia A

Acquired hemophilia A is a disease with high overall mortality despite appropriate treatment. According to the literature, overall mortality is 9-41%, and within the median follow-up period about 30-40% of deaths are due to bleeding (intracranial, intra-abdominal, gastrointestinal) and the remaining 30-40% to opportunistic infection related to immunosuppressive treatment. The complete remission rate with immunosuppressive therapy is 60-80%, and the relapse rate after complete remission is about 10-20%. Known poor prognostic factors are advanced age (≥65 years), FVIII activity <1 IU/dL, inhibitor titer >20 BU/mL, and accompanying malignancy. In the latest study introducing emicizumab (GTH-AHA-EMI, 2025), a strategy of emicizumab first followed by delayed immunosuppressive therapy was reported to reduce infectious complications and improve the survival benefit. Pregnancy-related acquired hemophilia A has a relatively high spontaneous remission rate and a relatively favorable prognosis.

Amyloidosis-related acquired FX deficiency

FX deficiency is an independent poor prognostic factor for survival in patients with AL amyloidosis. The lower the FX activity, the higher the bleeding-related mortality, and the key strategy is to maintain FX with bypassing therapy such as splin transfusion while at the same time seeking FX recovery through treatment of the underlying amyloidosis. FX may normalize when a complete hematologic response is achieved after autologous stem cell transplantation.

Follow-up

After complete remission of acquired hemophilia A, FVIII activity and the inhibitor are monitored periodically (monthly at first, then at 3-month intervals) to detect relapse early. Closer follow-up is needed for one year after discontinuation of immunosuppression. When an underlying malignancy or autoimmune disease is present, the activity of that disease and the activity of acquired hemophilia are monitored in parallel. When the cause of vitamin K deficiency has not been corrected (malabsorption, etc.), continuous vitamin K supplementation is needed.


12. Prevention

Prevention of acquired coagulation factor deficiency differs in strategy by cause: in some cases complete primary prevention is possible, and in others surveillance of the underlying disease and early detection are key.

Prevention of vitamin K deficiency

Vitamin K deficiency is a preventable acquired coagulation factor deficiency. Maintaining a balanced diet (vitamin K-rich foods such as green leafy vegetables and fermented foods) is the basis. In patients receiving broad-spectrum antibiotics (especially drugs containing the cephalosporin NMTT group, or taken for 2 weeks or longer), patients on prolonged fasting or total parenteral nutrition, and patients with malabsorptive disease, prophylactic vitamin K₁ supplementation (oral 5-10 mg/week or intravenous injection) is recommended. To prevent vitamin K deficiency bleeding in neonates, intramuscular vitamin K₁ 1 mg immediately after birth (or oral administration followed by repeated dosing) is standard.

Prevention of warfarin-related acquired coagulation factor deficiency

In patients taking warfarin, regular monitoring is essential to prevent departure of INR from the therapeutic range. When an interacting drug (antibiotics, NSAIDs, antifungals, anticonvulsants, etc.) is added or changed, INR is rechecked early. Dose readjustment is needed with dietary changes that cause large changes in vitamin K content. Pharmacogenomic calculation of the initial warfarin dose based on VKORC1 and CYP2C9 genotype can reduce the risk of over-anticoagulation. Where there is an appropriate indication, switching to a direct oral anticoagulant (DOAC) can be considered, which eliminates the need for INR monitoring.

Prevention of liver disease-related coagulopathy

Prevention of liver disease itself and inhibition of its progression are key. Hepatitis B and C vaccination, early antiviral treatment for HBV infection, cure with HCV direct-acting antivirals (DAA), abstaining from excessive alcohol, and management of nonalcoholic fatty liver (weight loss, control of metabolic syndrome) prevent progression to cirrhosis. In patients with cirrhosis, the coagulation status is assessed before procedures with high bleeding risk (endoscopic biopsy, paracentesis, surgery, etc.) and a correction plan is established if needed.

Prevention of autoantibody inhibitor development

Complete primary prevention of coagulation factor deficiency due to autoantibody inhibitors such as acquired hemophilia A is currently not possible. However, recognition of risk factors and early diagnosis are the best approach. When unexplained bleeding symptoms occur in patients with autoimmune disease or hematologic malignancy, early coagulation testing is performed. Vigilance is needed for the development of FV inhibitors in patients exposed to bovine thrombin (especially repeated cardiac surgery and neurosurgery), and using human thrombin in surgery where possible is desirable.

Bleeding prevention before invasive procedures

In patients with known acquired coagulation factor deficiency, a sufficient advance coagulation correction plan is essential to prevent bleeding during invasive procedures, surgery, and delivery. Prior consultation with a hemophilia treatment specialist (hematologist), preparation of appropriate coagulation factor replacement or bypassing agents, and securing blood products in preparation for emergencies are standard procedure. All patients with acquired coagulation factor deficiency are recommended to carry a medical alert card (medical alert ID) and to have a system in place enabling prompt care in an emergency.


13. References

  1. Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112(2):250-255. DOI: 10.1182/blood-2008-03-143586. PMID: 18497320.

  2. Knoebl P, Marco P, Baudo F, et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631. DOI: 10.1111/j.1538-7836.2012.04654.x. PMID: 22321904.

  3. Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695-705. DOI: 10.1002/ajh.24777. PMID: 28370181.

  4. Coppola A, Favaloro EJ, Tufano A, et al. Management of rare acquired bleeding disorders. Hematology Am Soc Hematol Educ Program. 2019;2019(1):80-86. DOI: 10.1182/hematology.2019000044. PMID: 31808835.

  5. Lee H, Lee MJ, Baek HJ, et al. Acquired Factor X Deficiency in Light Chain Amyloidosis: A Report of 2 Korean Cases. Korean J Hematol. 2011;46(2):141-145. PMC: PMC3129344.

  6. Tiede A, Hofbauer CJ, Werwitzke S, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AHA 01/2010 study. Blood. 2016;127(19):2289-2297. DOI: 10.1182/blood-2015-11-681064. PMID: 26903548.

  7. Saleem MM, Dahl MV, Müller J, et al. Acquired hemophilia A as a disease of the elderly: A comprehensive review of epidemiology, pathogenesis, and novel therapy. GeroScience. 2025;47:3261-3275. DOI: 10.1007/s11357-024-01317-7. PMC: PMC11872964.

  8. Tiede A, Klamroth R, Oldenburg J, et al. Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A. Blood Advances. 2025;9(22):5853-5862. DOI: 10.1182/bloodadvances.2025016557.

  9. Patriquin CJ, Crowther MA. Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol. 2011;4(6):657-667. DOI: 10.1586/ehm.11.60. PMID: 22077527.

  10. Peyvandi F, Kaviani S, Shafaee A, et al. The global epidemiology of acquired factor X deficiency. Hematology. 2025;30(1). DOI: 10.1080/16078454.2025.2476254.